Factors Affecting the Survival of Therapy Related AML/MDS, Secondary AML and De Novo AML

被引：0
|
作者：
Mushtaq, Rao [1 ]
Akbar, Faisal [2 ]
Khan, Israa [3 ]
Isom, Scott [4 ]
Pardee, Timothy [4 ]
Howard, Dianna S. [4 ]
Powell, Bayard L. [4 ]
机构：
[1] Univ Colorado, Aurora, CO USA
[2] Wake Forest Univ, Dept Med, Lewisville, NC USA
[3] Univ Colorado, Sch Med, Childrens Hosp Colorado, Dept Pediat Hosp Med, Aurora, CO USA
[4] Wake Forest Baptist Hlth, Comprehens Canc Ctr, Winston Salem, NC USA
来源：
BLOOD | 2018年 / 132卷
关键词：
D O I：
10.1182/blood-2018-99-110191
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5199
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Reasons for treating secondary AML as de novo AML
    Ostgard, Lene Sofie Granfeldt
    Kjeldsen, Eigil
    Holm, Mette Skov
    Brown, Peter De Nully
    Pedersen, Bjarne Bach
    Bendix, Knud
    Johansen, Preben
    Kristensen, Jorgen Scholer
    Norgaard, Jan Maxwell
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2010, 85 (03) : 217 - 226
  • [2] CLINICAL-BIOLOGICAL ANALYSIS AND SURVIVAL IN SECONDARY AML: AML WITH MYELODYSPLASIA-RELATED CHANGES AND AML RELATED TO THERAPY
    Camacho Inmaculada, Fernandez
    Hernandez Francisco, Salas
    Rodriguez Elena, Paumard
    Losada Carmen, Martinez
    Lopez Josefina, Serrano
    Garcia Joaquin, Sanchez
    HAEMATOLOGICA, 2020, 105 : 51 - 52
  • [3] COMPARISON BETWEEN IMMUNOGENOTYPIC FINDINGS IN DE-NOVO AML AND AML POST MDS
    OHYASHIKI, JH
    OHYASHIKI, K
    KAWAKUBO, K
    FUJIMURA, T
    SHIMAMOTO, T
    NAKAZAWA, S
    KIMURA, N
    TOYAMA, K
    LEUKEMIA, 1993, 7 (11) : 1747 - 1751
  • [4] Comparing Outcomes of Patients with Secondary AML: Treatment-Related MDS/AML, AML Secondary to Myeloproliferative Neoplasms (t-MPN), and AML with Prior Malignancies
    Arana, Cecilia Y.
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    Wierda, William G.
    Borthakur, Gautam
    Quintas-Cardama, Alfonso
    Konopleva, Marina
    Faderl, Stefan
    Pierce, Sherry A.
    Andreeff, Michael
    Ravandi, Farhad
    Cortes, Jorge E.
    BLOOD, 2012, 120 (21)
  • [5] Clonal Hematopoiesis and therapy related MDS/AML
    Desai, Pinkal
    Roboz, Gail J.
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2019, 32 (01) : 13 - 23
  • [6] Bone Marrow Cellularity during Induction Is Highly Predictive of Complete Remission in De Novo AML but Not in Secondary/Therapy-Related AML
    Zheng, G.
    DeZern, A. E.
    Pratz, K. W.
    Karp, J. E.
    Gocke, C. D.
    MODERN PATHOLOGY, 2012, 25 : 384A - 385A
  • [7] Bone Marrow Cellularity during Induction Is Highly Predictive of Complete Remission in De Novo AML but Not in Secondary/Therapy-Related AML
    Zheng, G.
    DeZern, A. E.
    Pratz, K. W.
    Karp, J. E.
    Gocke, C. D.
    LABORATORY INVESTIGATION, 2012, 92 : 384A - 385A
  • [8] Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantation
    Armand, Philippe
    Kim, Haesook T.
    DeAngelo, Daniel J.
    Ho, Vincent T.
    Cutler, Corey S.
    Stone, Richard M.
    Ritz, Jerome
    Alyea, Edwin P.
    Antin, Joseph H.
    Soiffer, Robert J.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2007, 13 (06) : 655 - 664
  • [9] Different Incidence and Implications of DNA Hypermethylation in De Novo AML Compared to High-Risk MDS and AML Following MDS
    Deneberg, Stefan
    Groevdall, Michael
    Jansson, Monika
    Gaidzik, Verena I.
    Corbacioglu, Andrea
    Nahi, Hareth
    Bengtzen, Sofia
    Doehner, Konstanze
    Paul, Christer
    Hellstroem-Lindberg, Eva
    Lehmann, Soeren
    BLOOD, 2008, 112 (11) : 1146 - 1147
  • [10] Different pattern of JNK activity in MDS-related versus de novo AML: implications for apoptosis-resistance and treatment failure in MDS-related AML
    Lagadinou, E. D.
    Ziros, P.
    Tsopra, O.
    Klamargias, A.
    Thanopoulou, E.
    Kouraklis, A.
    Spyridonidis, A.
    Karakantza, M.
    Zoumbos, N. C.
    LEUKEMIA RESEARCH, 2007, 31 : S54 - S55
12345